November 12–16, 2018
Meet Genedata experts at PEGS Europe in Lisbon, Portugal.
Don't miss the opportunity to see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, and quality control of biologicals.
To get more information about Genedata solutions, please contact firstname.lastname@example.org.
Characterization of Complex Glycosylation Patterns for Biopharmaceuticals
Urs Lohrig, PhD, Labhead AL1, Global Drug Development / Technical, Research & Development, Novartis
Analytical Characterisation of Biotherapeutics Session
Wednesday, November 14 | 16:15–16:45
Glycosylation remains a major challenge when probing the molecular structure of biopharmaceuticals. Tools for the in-depth characterization of N- and O-glycosylations have been developed over the years and were employed on various levels within the industry.Here, we present approaches including hyphenated LC-MS/MS on various levels to tackle the complexity of glycan modifications within biosimilar characterization workflows. This enables a suitable depth of knowledge for manufacturing process developmentas well as supporting final biosimilarity evaluation.
Industrializing IO Therapeutic Discovery Platforms: Multispecifics, Engineered TCRs and CAR Ts
Maria Wendt, PhD, Head of Science, Biologics, Genedata
FC Engineering for Enhanced Product Properties and for Brain Delivery Session
Friday, November 16 | 11:35–12:05
Novel classes of bio-molecules are currently evaluated for their use in cancer immunotherapy. Bi- and multi-specific antibodies, Ab-cytokine fusion proteins, non-Ig scaffolds, chimeric antigen receptors (CARs), engineered TCRs and TCR-based bispecific constructs promise significant advantages. However, these highly engineered molecules pose new challenges in design, engineering, cloning, expression, purification, and analytics. Genedata Biologics offers an infrastructure that addresses these challenges and enables the industrialization of these various novel therapeutic platforms.
Industrializing IO Therapeutic Discovery Platforms: Multispecifics, Engineered TCRs and CARs
A Platform Approach to Manage Developability and Manufacturability Risks of Biologics Molecules
End-to-End Workflow Platform for Integrated Biopharmaceutical Development
Automated Data Processing and Analysis for Quality Monitoring of Biotherapeutics by Multi-attribute Method (MAM)
An automated approach for comprehensive characterization and quantification of low-abundance sequence variants in a standard monoclonal antibody
Large-scale determination of affinity, specificity, and kinetics of complex molecules: Automating data analysis at pace with the new possibilities
Stephan Steigele, Lope Florez, Martin Ginkel, Renee Emkey, Leigh Foster and Stephan Heyse